Vyleesi vs Addyi: What Real Prescribing Data Shows

Vyleesi and Addyi are reaching similar specialists, but the path to each prescription is more different than the drugs themselves. A new April 7, 2026 abstract from Rutgers mapped real prescribing data and found that both HSDD medications land mostly with OB/GYNs, but Vyleesi is pulling much stronger commercial-insurance coverage. That gap in access may matter as much as the delivery method.

What the research actually shows

Researchers at Rutgers analyzed real prescriber data from both manufacturers—covering January 2019 through October 2025—and cross-checked patterns against Google Trends. The snapshot they found was striking in its consistency: average patient age was nearly identical (45.5 for Vyleesi, 43.5 for Addyi), OB/GYNs prescribed both medications at roughly the same rate (about 40% each), and urologists accounted for just a tiny slice in both cases (2% to 4%). But the insurance story diverged sharply. About 81% of Vyleesi prescriptions were covered by commercial insurance versus just 50% for Addyi —a gap that hinted at something deeper about real-world access and who can actually get each drug.

• Prescribing patterns were remarkably similar overall: same specialists, same patient ages, same geographic spread nationwide.
• Vyleesi has significantly stronger commercial-insurance coverage (81% vs 50%), suggesting access architecture matters as much as the drug.
• Search behavior still favored symptom-first language over formal HSDD terminology, but the clinical pathway was increasingly clear.

Why this gap between access and delivery matters

The prescribing numbers are interesting, but the real story is simpler: these two drugs solve a different problem. Vyleesi is an on-demand subcutaneous injection for premenopausal women, designed for the moment before sex, while Addyi is a once-daily bedtime pill now labeled for women younger than 65. That fundamental difference means this abstract isn't about which drug is 'winning'—it's about how clinicians are matching the routine that fits your life, your insurance, and your preference. If you want to understand the Vyleesi connection to PT-141, PT-141 Is Vyleesi: The Approved U.S. Formulation and Why It Matters is the best starting point.

The insurance split is where things get interesting

An on-demand injection pulling 81% commercial coverage while a daily pill sits at 50% suggests that convenience alone isn't driving the difference. Instead, formulary design, prior authorization, and who your insurance actually covers may be sorting patients as much as clinical preference. That pattern holds up in follow-on April 21 reporting, which again showed OB/GYNs leading prescriptions nationwide—and revealed that real-world HSDD treatment is already moving into older patient populations, even as labels catch up.

What this abstract does and doesn't tell you

This is a prescribing snapshot, not a full efficacy comparison or a complete claims analysis. The abstract doesn't tell you which drug works better for you, how many people stick with each therapy over time, or how insurance barriers shaped the initial numbers. For that patient-facing context—what Vyleesi actually feels like and what side effects matter— PT-141 Review: The Libido Lift and the Side Effects is the clearer read.

What this means for you

The real takeaway isn't that one drug is 'winning'—it's that the U.S. HSDD market is becoming clearer and more segmented. Both drugs are rooted in OB/GYN practices, both are reaching similar patient ages, but Vyleesi has carved out a stronger commercial-insurance footprint while Addyi's broader label expansion is opening access for older women. The choice between them is coming down to routine, access, and what fits your life. If you're still weighing bremelanotide delivery options more broadly, PT-141 Nasal Spray: The Dosing Routine That Shapes Results shows how routine shapes outcomes.